Sickle cell anaemia gene therapy - ValiGenAlternative Names: Chimeraplasts; Chimeric oligonucleotides
Latest Information Update: 17 Mar 2008
At a glance
- Originator ValiGen
- Class Gene therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Sickle cell anaemia
Most Recent Events
- 21 Jun 2000 Kimeragen has merged with ValiGene to form ValiGen
- 29 Apr 1997 Preclinical development for Sickle cell anaemia in USA (unspecified route)